Moreover, it has been found that IPF with mutations in TERT, RTEL1, or PARN has a significantly higher risk of death and chronic lung allograft dysfunction compared to those in patients without these mutations (79, 80). This evidence concerns the gene PARN and chronic lung allograft dysfunction.